Scarica l'app Stockscreener
1.62
2.53%
0.04
Pre-mercato:
1.68
0.06
+3.70%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ADIL Giù?
Forum
Previsione
Frazionamento azionario
Adial Pharmaceuticals Inc Borsa (ADIL) Ultime notizie
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
ADIL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Published on: 2026-04-10 14:04:42 - baoquankhu1.vn
Adial Pharmaceuticals Files 8-K on Executive Changes and Restricted Stock Award Agreement - Minichart
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan - TipRanks
Adial Pharmaceuticals grants restricted stock awards to Cary Claiborne, Vinay Shah and Tony Goodman - TradingView
[Form 4] ADIAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Adial Pharmaceuticals (ADIL) director receives 9,185 stock options at $1.64 strike - Stock Titan
Adial (NASDAQ: ADIL) awards RSAs and stock options to board members - Stock Titan
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
Adial Pharmaceuticals (ADIL) CFO receives 17,325-share restricted stock grant - Stock Titan
ADIAL (ADIL) director awarded 9,185 restricted shares in equity grant - Stock Titan
Adial Pharmaceuticals (NASDAQ: ADIL) CEO granted 37,985 shares - Stock Titan
Investor Mood: Will Adial Pharmaceuticals Inc benefit from government policy2026 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Hedge Fund Bets: Whats the MACD signal for Adial Pharmaceuticals Inc2026 Dividend Review & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Market Moves: Whats Adial Pharmaceuticals Incs historical returnDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
Aug Closing: Does Adial Pharmaceuticals Inc offer margin of safetyStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Valuation Update: Will Adial Pharmaceuticals Inc benefit from geopolitical trends2026 Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder - Sahm
Adial Pharmaceuticals Commends Introduction of H.R. 7091 to Expand Access to Alcohol Use Disorder Treatments for Veterans - Quiver Quantitative
Adial Pharmaceuticals Commends Congress on Introduction of - GlobeNewswire
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans - The Manila Times
Smart Money: Does Adial Pharmaceuticals Inc have a competitive edge2026 Trade Ideas & Daily Stock Trend Reports - baoquankhu1.vn
Nasdaq Moves: Whats the beta of Adial Pharmaceuticals Inc stock2026 Analyst Calls & Real-Time Volume Analysis - baoquankhu1.vn
Revenue per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
Tech Rally: Whats the fair value of Adial Pharmaceuticals Inc stockPortfolio Risk Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Is Adial Pharmaceuticals Inc. stock a smart buy before Fed meetingPortfolio Return Report & High Conviction Investment Ideas - Naître et grandir
Key facts: Adial Pharmaceuticals reports $7.98M annual loss; 2025 results show regulatory progress - TradingView
Adial Pharmaceuticals (ADIL) Enhances Financial Position and Cli - GuruFocus
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update - TradingView
Adial Pharmaceuticals (NASDAQ: ADIL) outlines AD04 advances, Europe deal and Nasdaq win - Stock Titan
Adial Pharmaceuticals 10-K: $(7.98M) Net Loss, $(11.93) EPS; Cash into H2 2026 - TradingView
Adial Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ADIL SEC FilingsAdial Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Adial Pharmaceuticals signs framework deal with Molteni for Europe By Investing.com - Investing.com Canada
Adial Pharmaceuticals (ADIL) Plans European Expansion for AD04 w - GuruFocus
Adial Pharmaceuticals signs exclusive AD04 collaboration framework with Molteni Farmaceutici for Europe - marketscreener.com
Adial Pharmaceuticals signs framework deal with Molteni for Europe - Investing.com
Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization - TipRanks
Adial Pharmaceuticals enters exclusive AD04 Europe framework with Molteni; potential $60M in royalties & milestones - TradingView
Adial (NASDAQ: ADIL) outlines AD04 Europe deal framework with Molteni - Stock Titan
Adial Pharmaceuticals, Inc. Enters into A Collaboration Framework Agreement with Molteni Farmaceutici - marketscreener.com
EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Adial Pharmaceuticals (ADIL) to Release Quarterly Earnings on Tuesday - Defense World
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One - ADVFN Ltd
Adial Pharmaceuticals, IncWarrant (NQ: ADILW - The Chronicle-Journal
Adial Pharmaceuticals Secures Exchange Listing Amid Regulatory Tailwinds - AD HOC NEWS
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 87.7% - Defense World
ADIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program - The Globe and Mail
ARMISTICE CAPITAL, LLC Acquires Shares in Adial Pharmaceuticals Inc - GuruFocus
Key facts: Adial Pharmaceuticals meets Nasdaq bid requirement; advances AD04 to Phase 3 trial - TradingView
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement - Bitget
Adial Pharmaceuticals regains full compliance with Nasdaq listing requirement - marketscreener.com
Adial Regains Nasdaq Compliance as AD04 Advances, Engages in Partnering Talks - TradingView
Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement - TradingView
Adial Pharmaceuticals (ADIL) regains Nasdaq compliance, highlights AD04 Phase 3 path - Stock Titan
Adial Pharmaceuticals eyes single pivotal trial path for AD04 - Investing.com India
Adial Pharmaceuticals eyes single pivotal trial path for AD04 By Investing.com - Investing.com Australia
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):